{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-007862","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.321824+00:00","generated_at":"2026-05-25T02:08:48.054465+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Senti Biosciences appoints Feng Hsiung to board, stockholders approve 4.3M share increase in equity plan","bullets":["Feng Hsiung appointed to board as Class III director effective March 7, 2025; also joins audit committee.","Stockholders approved Amended 2022 Equity Incentive Plan adding 4,300,000 shares and extending term to 2035.","Board adopted Amended Inducement Plan reserving extra 500,000 shares for new-hire inducement grants.","Non-employee director compensation policy revised; each continuing director received 43,900-share option grant.","CEO Timothy Lu received contingent option for 1,927,073 shares and RSU for 642,358 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-007862","json":"https://secwatch.observer/filing/0001140361-25-007862.json","markdown":"https://secwatch.observer/filing/0001140361-25-007862.md","text":"https://secwatch.observer/filing/0001140361-25-007862.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000114036125007862/0001140361-25-007862-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000114036125007862/ef20045153_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T02:08:48.054465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"034616288a","claim":"Feng Hsiung was appointed as Class III Director at Senti Biosciences, Inc..","evidence_excerpt":"On March 7, 2025, the Board of Directors (the “Board”) of Senti Biosciences, Inc. (the “Company”) approved the appointment of Feng Hsiung to the Board, pursuant to the terms of a letter agreement dated as of December 2, 2024, by and between the Company and Celadon Partners SPV 24.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000114036125007862/0001140361-25-007862-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}